Simufilam for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 6 registered trials.

Why this status

  1. 6 Aug 2021: Trial registered, NCT04994483
  2. 3 Nov 2021: Trial started, NCT04994483

The trials

NCT03748706: PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

State
Completed
Phase
Phase 2
People
13 taking part
Started
7 Mar 2019
Primary completion
8 May 2019
Arms
Simufilam (PTI-125)
Results
Posted on the registry
  1. 21 Nov 2018: Trial registered
  2. 7 Mar 2019: Trial started
  3. 8 May 2019: Trial completed
  4. 1 Apr 2021: Trial results posted

NCT04079803: PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

State
Completed
Phase
Phase 2
People
64 taking part
Started
9 Sep 2019
Primary completion
31 Mar 2020
Arms
Simufilam (PTI-125) 100 mg tablets Cohort, Simufilam (PTI-125) 50 mg tablets Cohort
Results
Posted on the registry
  1. 6 Sep 2019: Trial registered
  2. 9 Sep 2019: Trial started
  3. 31 Mar 2020: Trial completed
  4. 1 Jun 2021: Trial results posted

NCT04994483: Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

State
Completed
Phase
Phase 3
People
804 taking part
Started
3 Nov 2021
Primary completion
2 Oct 2024
Arms
Simufilam 100 mg
Results
Posted on the registry
  1. 6 Aug 2021: Trial registered
  2. 3 Nov 2021: Trial started
  3. 2 Oct 2024: Trial completed
  4. 25 May 2025: Trial results posted

NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

State
Stopped early
Phase
Phase 3
People
1,125 taking part
Started
18 Nov 2021
Primary completion
30 Dec 2024
Arms
Simufilam 50 mg, Simufilam 100 mg
Results
Posted on the registry
  1. 30 Aug 2021: Trial registered
  2. 18 Nov 2021: Trial started
  3. 30 Dec 2024: Trial terminated
  4. 22 Sep 2025: Trial results posted

NCT05352763: Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

State
Stopped early
Phase
Phase 2
People
90 taking part
Started
12 May 2022
Primary completion
31 Dec 2024
Arms
Simufilam 100 mg
Results
Posted on the registry
  1. 29 Apr 2022: Trial registered
  2. 12 May 2022: Trial started
  3. 31 Dec 2024: Trial terminated
  4. 15 Aug 2025: Trial results posted

NCT05575076: Open-label Extension for Phase 3 Clinical Trials of Simufilam

State
Stopped early
Phase
Phase 3
People
1,081 taking part
Started
7 Nov 2022
Primary completion
31 Jan 2025
Arms
Simufilam 100 mg
Results
Posted on the registry
  1. 12 Oct 2022: Trial registered
  2. 7 Nov 2022: Trial started
  3. 31 Jan 2025: Trial terminated
  4. 14 May 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as PTI-125, 100 mg tablets, Simufilam 100 mg tablet, Simufilam 50 mg oral tablet.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.